Safety of SARS-CoV-2 mRNA vaccines and effects of immunosuppressive drugs on adverse reactions in patients with rheumatic diseases.
作者信息
Kawazoe Mai, Nishio Junko, Hirose Wataru, Furukawa Karin, Nanki Toshihiro
机构信息
Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo 143-8541, Japan.
Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo 143-8541, Japan; Department of Immunopathology and Immunoregulation, Toho University School of Medicine, Japan.
出版信息
Eur J Intern Med. 2023 Sep;115:137-139. doi: 10.1016/j.ejim.2023.06.014. Epub 2023 Jun 16.
Abstract
摘要
相似文献
1
Safety of SARS-CoV-2 mRNA vaccines and effects of immunosuppressive drugs on adverse reactions in patients with rheumatic diseases.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗的安全性以及免疫抑制药物对风湿性疾病患者不良反应的影响。
Eur J Intern Med. 2023 Sep;115:137-139. doi: 10.1016/j.ejim.2023.06.014. Epub 2023 Jun 16.
2
Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases.罕见风湿性疾病患者接种BNT162b2 mRNA新冠疫苗后的安全性及疾病复发低风险
J Rheumatol. 2022 Mar;49(3):334-335. doi: 10.3899/jrheum.210863. Epub 2022 Jan 15.
3
Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease.风湿性和肌肉骨骼疾病患者接种第三剂严重急性呼吸综合征冠状病毒2疫苗的安全性。
Rheumatology (Oxford). 2022 Oct 6;61(10):e302-e304. doi: 10.1093/rheumatology/keac298.
4
Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.炎症性风湿病患者接种 SARS-CoV-2 疫苗：疫苗广泛可用前的考虑因素。
RMD Open. 2021 Feb;7(1). doi: 10.1136/rmdopen-2020-001553.
5
Correspondence on "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry" by Machado .关于马查多所著的《风湿性和肌肉骨骼疾病患者接种新型冠状病毒疫苗的安全性：欧洲抗风湿病联盟冠状病毒疫苗（COVAX）医生报告登记处的结果》的通信
Ann Rheum Dis. 2023 Dec;82(12):e228. doi: 10.1136/annrheumdis-2022-222118. Epub 2022 Jul 11.
6
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.在一项单中心队列研究中，慢性炎症性疾病和免疫抑制治疗患者的抗 SARS-CoV-2 mRNA 疫苗的免疫原性和安全性。
Ann Rheum Dis. 2021 Oct;80(10):1306-1311. doi: 10.1136/annrheumdis-2021-220272. Epub 2021 Mar 24.
7
An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.一项针对风湿和免疫介导性疾病患者的阿根廷队列研究：SARS-CoV-2 疫苗接种：SAR-CoVAC 注册研究方案和初步数据。
Clin Rheumatol. 2022 Oct;41(10):3199-3209. doi: 10.1007/s10067-022-06253-5. Epub 2022 Jun 28.
8
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases.mRNA新型冠状病毒2疫苗首剂在风湿性和肌肉骨骼疾病患者中的安全性。
Ann Rheum Dis. 2021 Aug;80(8):1100-1101. doi: 10.1136/annrheumdis-2021-220231. Epub 2021 Mar 19.
9
Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study.青少年和年轻成年人风湿性疾病患者 COVID-19 疫苗相关不良事件的早期经验：一项单中心研究。
Int J Rheum Dis. 2022 Mar;25(3):353-363. doi: 10.1111/1756-185X.14279. Epub 2022 Jan 3.
10
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.BNT162b2 mRNA COVID-19 疫苗在成年自身免疫性炎症性风湿病患者和普通人群中的免疫原性和安全性：一项多中心研究。
Ann Rheum Dis. 2021 Oct;80(10):1330-1338. doi: 10.1136/annrheumdis-2021-220647. Epub 2021 Jun 14.
Zotero 插件